Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.

Int J Chron Obstruct Pulmon Dis · 2018 · PMC6016010 · PMID 29950826

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

For the proportion of patients achieving ≥12% improvement in FEV 1 , none of the pairwise comparisons between any of the GFF MDI doses and GP MDI 36 μg were nominally significant ( Table 2 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.